Nascent Biotech, Inc. (OTCMKTS:NBIO – Get Free Report) passed below its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $0.12 and traded as low as $0.10. Nascent Biotech shares last traded at $0.10, with a volume of 1,700 shares traded.
Nascent Biotech Stock Performance
The company has a 50-day simple moving average of $0.12 and a 200-day simple moving average of $0.15.
About Nascent Biotech
Nascent Biotech, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer.
Read More
- Five stocks we like better than Nascent Biotech
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- High-Yield Texas Instruments Could Hit New Highs Soon
- Following Congress Stock Trades
- Pagaya Technologies: An AI Fintech That Insiders Are Buying
- What is the Nikkei 225 index?
- Higher Oil Prices Could Give NextEra’s Stock Earnings a Boost
Receive News & Ratings for Nascent Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nascent Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
